Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2013-01-31
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ProTectis
ProTectis
Gastrus
Gastrus
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ProTectis
Gastrus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary IgAN, verified by biopsy
* Albuminuria \> 0.75 g/24 h (verified by at least four sample results within a two years period prior to inclusion)
* Serum creatinine less than 200 umol/L (verified by at least four sample results within a two years period prior to inclusion)
* Having signed informed consent form
Exclusion Criteria
* Patients with celiac disease
* Patients with secondary IgAN
* Creatinine clearance below 30 ml/min (mean of 3 measurements)
* Introduction of an ACE inhibitor or angiotensin II receptor blocker during the last three months prior to inclusion
* Patients treated with immunosuppressive or systemic corticosteroid drugs within the last twelve months
* Patients using probiotic products within the last three months (includes probiotic milk products)
* Known allergy or intolerance to any of the ingredients in the probiotic product
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Linkoeping
OTHER
Karolinska Institutet
OTHER
Uppsala University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hilde Kloster Smerud
Clinical Research Scientist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Linköping University Hospital
Linköping, , Sweden
Karolinska University Hospital
Stockholm, , Sweden
Uppsala University Hosptial
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anders Fernström, MD PhD
Role: primary
Sigrid Lundberg, MD PhD
Role: primary
Bengt Fellström, MD PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMR-2712
Identifier Type: OTHER
Identifier Source: secondary_id
SMR-2712
Identifier Type: -
Identifier Source: org_study_id